Zydus Lifesciences shares in focus after FDA approval for prostate cancer drug
Zydus Lifesciences shares will be in focus on Wednesday after the company secured final approval from the US Food and Drug Administration (USFDA) to manufacture a generic version of Apalutamide tablets, used to treat prostate cancer. The approval covers Apalutamide tablets of 60 mg strength, the company said in a regulatory filing. The drug will…